We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Vasculitis during certolizumab pegol and secukinumab treatment: Report of two cases.
- Authors
Bostan, Ecem; Gulseren, Duygu; Yalici‐Armagan, Basak; Dogan, Sibel; Ates‐Ozdemir, Deniz; Gokoz, Ozay; Kalyoncu, Umut; Atakan, Nilgün
- Abstract
Even though biologic agents have a good overall safety profile, various immune-mediated cutaneous adverse events with these agents have been reported.1-5 Herein, we would like to report two patients who developed leukocytoclastic vasculitis (LCV) under certolizumab pegol and secukinumab treatment, respectively. Finally, it should be kept in mind that patients under biologic treatment are prone to develop various cutaneous adverse events; regular dermatologic examination is required for prompt diagnosis and treatment. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
- Subjects
PSORIATIC arthritis; VASCULITIS
- Publication
Dermatologic Therapy, 2021, Vol 34, Issue 4, p1
- ISSN
1396-0296
- Publication type
Article
- DOI
10.1111/dth.15007